Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients

Hepatology

Volumn 57, Issue 1, 2013, Pages 239-248

  Levitsky, Josh ^a   Mathew, James M ^a   Abecassis, Michael ^a   Tambur, Anat ^a   Leventhal, Joseph ^a   Chandrasekaran, Dhivya ^a   Herrera, Nancy ^a   Al Saden, Patrice ^a   Gallon, Lorenzo ^a   Abdul Nabi, Anmaar ^a   Yang, Guang Yu ^a   Kurian, Sunil M ^b   Salomon, Daniel R ^b   Miller, Joshua ^a,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID P COMPONENT; BLOOD CLOTTING FACTOR 7; CA 125 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD5 ANTIGEN; CD8 ANTIGEN; COLLAGEN TYPE 4; COMPLEMENT COMPONENT C3; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FERRITIN; GLUTATHIONE TRANSFERASE ALPHA; HAPTOGLOBIN; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 3; INTERLEUKIN 7; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PANCREAS POLYPEPTIDE; PROTEIN TYROSINE KINASE; RAPAMYCIN; SEX HORMONE BINDING GLOBULIN; STROMELYSIN; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ALLOGRAFT; ANEMIA; ARTICLE; BLOOD; BONE MARROW; BONE MARROW BIOPSY; CD4+ CD25+ T LYMPHOCYTE; CELL GROWTH; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DIARRHEA; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FLOW CYTOMETRY; FOOT ULCER; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENOMICS; GRAFT RECIPIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY DYSFUNCTION; LIVER BIOPSY; LIVER GRAFT; LIVER TRANSPLANTATION; LYMPHOCYTE COUNT; LYMPHOCYTE CULTURE; MALE; MIXED LYMPHOCYTE REACTION; NAUSEA; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL EDEMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REGULATORY T LYMPHOCYTE;

ADULT; AGED; BIOLOGICAL MARKERS; BONE MARROW; CD4-CD8 RATIO; FEMALE; HUMANS; IMMUNOMODULATION; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; LIVER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEOME; SIROLIMUS; TACROLIMUS; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 84865302248     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25579     Document Type: Article

References (45)

1. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-940.
2. Levitsky J. Operational tolerance: past lessons and future prospects. Liver Transpl 2011; 17: 222-232.
3. Sykes M. Chimerism and central tolerance. Curr Opin Immunol 1996; 8: 694-703.
4. Chatzipetrou MA, Mathew JM, Kenyon NS, Esquenazi V, Miller J, Ricordi C, Tzakis AG. Analysis of post-transplant immune status in recipients of liver/bone marrow allografts. Hum Immunol 1999; 60: 1281-1288.
5. Mazariegos GV, Zahorchak AF, Reyes J, Ostrowski L, Flynn B, Zeevi A, Thomson AW. Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am J Transplant 2003; 3: 689-696.
6. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006; 203: 1701-1711.
7. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061.
8. Li Y, Zhao X, Cheng D, Haga H, Tsuruyama T, Wood K, et al. The presence of Foxp3 expressing T cells within grafts of tolerant human liver transplant recipients. Transplantation 2008; 86: 1837-1843.
9. Martinez-Llordella M, Lozano JJ, Puig-Pey I, Orlando G, Tisone G, Lerut J, et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008; 118: 2845-2857.
10. Mathew JM, Fuller L, Carreno M, Garcia-Morales R, Burke GW, 3rd, Ricordi C, et al. Involvement of multiple subpopulations of human bone marrow cells in the regulation of allogeneic cellular immune responses. Transplantation 2000; 70: 1752-1760.
11. Miller J, Mathew J, Garcia-Morales R, Zucker KE, Carreno M, Jin Y, et al. The human bone marrow as an immunoregulatory organ. Transplantation 1999; 68: 1079-1090.
12. Fujisaki J, Wu J, Carlson AL, Silberstein L, Putheti P, Larocca R, et al. In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche. Nature 2011; 474: 216-219.
13. Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, Saidman SL, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358: 353-361.
14. Gao W, Lu Y, El Essawy B, Oukka M, Kuchroo VK, Strom TB. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant 2007; 7: 1722-1732.
15. Szabo G, Gavala C, Mandrekar P. Tacrolimus and cyclosporine A inhibit allostimulatory capacity and cytokine production of human myeloid dendritic cells. J Investig Med 2001; 49: 442-449.
16. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005; 105: 4743-4748.
17. Baan CC, van der Mast BJ, Klepper M, Mol WM, Peeters AM, Korevaar SS, et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 2005; 80: 110-117.
18. Hackstein H, Taner T, Zahorchak AF, Morelli AE, Logar AJ, Gessner A, Thomson AW. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003; 101: 4457-4463.
19. Levitsky J, Miller J, Wang E, Rosen A, Flaa C, Abecassis M, et al. Immunoregulatory profiles in liver transplant recipients on different immunosuppressive agents. Hum Immunol 2009; 70: 146-150.
20. Morard I, Dumortier J, Spahr L, Hadengue A, Majno P, Morel P, et al. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients. Liver Transpl 2007; 13: 658-664.
21. Levitsky J, Miller J, Leventhal J, Huang X, Flaa C, Wang E, et al. The human "Treg MLR": immune monitoring for FOXP3+ T regulatory cell generation. Transplantation 2009; 88: 1303-1311.
22. Levitsky J, Gallon L, Miller J, Tambur AR, Leventhal J, Flaa C, et al. Allospecific regulatory effects of sirolimus and tacrolimus in the human mixed lymphocyte reaction. Transplantation 2011; 91: 199-206.
23. Wertheimer AM, Bakke A, Rosen HR. Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease. HEPATOLOGY 2004; 40: 335-345.
24. Fathman CG, Collavo D, Davies S, Nabholz M. In vitro secondary MLR. I. Kinetics of proliferation and specificity of in vitro primed responder cells. J Immunol 1977; 118: 1232-1238.
25. Nakorchevsky A, Hewel JA, Kurian SM, Mondala TS, Campbell D, Head SR, et al. Molecular mechanisms of chronic kidney transplant rejection via large-scale proteogenomic analysis of tissue biopsies. J Am Soc Nephrol 2010; 21: 362-373.
26. Levitsky J, Salomon DR, Abecassis M, Langfelder P, Horvath S, Friedewald J, et al. Clinical and plasma proteomic markers correlating with chronic kidney disease after liver transplantation. Am J Transplant 2011; 11: 1972-1978.
27. Oo YH, Weston CJ, Lalor PF, Curbishley SM, Withers DR, Reynolds GM, et al. Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. J Immunol 2010; 184: 2886-2898.
28. Zeevi A. Propagation of lymphoid cells from biopsies. In: Hahn A, Land GA, Rosemarie MS, eds. American Society of Histocompatibility Laboratory Manual, 4th ed. (vol. 1). Mt. Laurel, NJ: American Society for Histocompatibility and Immunogenetics; 2000.
29. Poindexter NJ, Steward NS, Shenoy S, Brennan DC, Lowell J, Singer G, et al. Renal allograft infiltrating lymphocytes: frequency of tissue specific lymphocytes. Hum Immunol 1997; 55: 140-147.
30. Eisenhart C. The assumptions underlying the analysis of variance. Biometrics 1947; 3: 1-21.
31. Li Y, Koshiba T, Yoshizawa A, Yonekawa Y, Masuda K, Ito A, et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant 2004; 4: 2118-2125.
32. Mathew JM, Carreno M, Fuller L, Ricordi C, Tzakis A, Esquenazi V, Miller J. Modulatory effects of human donor bone marrow cells on allogeneic cellular immune responses. Transplantation 1997; 63: 686-692.
33. Manavalan JS, Rossi PC, Vlad G, Piazza F, Yarilina A, Cortesini R, et al. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl Immunol 2003; 11: 245-258.
34. Kowalski RJ, Post DR, Mannon RB, Sebastian A, Wright HI, Sigle G, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006; 82: 663-668.
35. Cookson S, Doherty DG, Todryk S, Gibbs P, Portmann B, O'Grady J, et al. Hepatic expression of IL-15 mRNA is associated with liver graft acceptance. Transpl Immunol 2003; 11: 39-48.
36. Nikolaeva N, Bemelman FJ, Yong SL, van Lier RA, ten Berge IJ. Rapamycin does not induce anergy but inhibits expansion and differentiation of alloreactive human T cells. Transplantation 2006; 81: 445-454.
37. Bestard O, Cunetti L, Cruzado JM, Lucia M, Valdez R, Olek S, et al. Intragraft regulatory T cells in protocol biopsies retain Foxp3 demethylation and are protective biomarkers for kidney graft outcome. Am J Transplant 2011; 11: 2162-2172.
38. Chiang PH, Wang L, Bonham CA, Liang X, Fung JJ, Lu L, Qian S. Mechanistic insights into impaired dendritic cell function by rapamycin: inhibition of Jak2/Stat4 signaling pathway. J Immunol 2004; 172: 1355-1363.
39. Turnquist HR, Raimondi G, Zahorchak AF, Fischer RT, Wang Z, Thomson AW. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol 2007; 178: 7018-7031.
40. Creput C, Le Friec G, Bahri R, Amiot L, Charpentier B, Carosella E, et al. Detection of HLA-G in serum and graft biopsy associated with fewer acute rejections following combined liver-kidney transplantation: possible implications for monitoring patients. Hum Immunol 2003; 64: 1033-1038.
41. Zeiser R, Nguyen VH, Beilhack A, Buess M, Schulz S, Baker J, et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006; 108: 390-399.
42. Lim DG, Koo SK, Park YH, Kim Y, Kim HM, Park CS, et al. Impact of immunosuppressants on the therapeutic efficacy of in vitro-expanded CD4+CD25+Foxp3+ regulatory T cells in allotransplantation. Transplantation; 89: 928-936.
43. Taner T, Hackstein H, Wang Z, Morelli AE, Thomson AW. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant 2005; 5: 228-236.
44. Manavalan JS, Kim-Schulze S, Scotto L, Naiyer AJ, Vlad G, Colombo PC, et al. Alloantigen specific CD8+CD28- FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity. Int Immunol 2004; 16: 1055-1068.
45. Patsenker E, Schneider V, Ledermann M, Saegesser H, Dorn C, Hellerbrand C, Stickel F. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol 2011; 55: 388-398.